AL-LAD vs LSZ

AL-LAD (6-allyl-6-nor-LSD) is a lysergamide psychedelic closely related to LSD, differing by replacement of the N6 methyl group with an allyl group. Like other serotonergic hallucinogens it acts primarily through agonism at the 5-HT2A receptor, and in the mouse head-twitch response assay it produces the characteristic inverted U-shaped dose-response curve, proving only slightly less potent than LSD itself. Users describe strongly visual, colorful effects with a duration comparable to LSD but often somewhat shorter and milder in strength and comedown. Analytical and metabolic studies have detailed its structure, biotransformation, and its acylated prodrug forms such as 1P-AL-LAD and 1cP-AL-LAD, which are hydrolyzed to AL-LAD in the body. A published case of fatal ventricular dysrhythmia associated with its use indicates that, despite its reputation as a gentler LSD analogue, it is not without cardiovascular risk.

effects

Serotonin

targets

5-HT2A receptor, 5-HT2C receptor, 5-HT1A receptor

suppliers

reference only

LSZ ((2'S,4'S)-lysergic acid 2,4-dimethylazetidide) is a lysergamide psychedelic in which the diethylamide of LSD is constrained within a rigid azetidine ring, fixing the amide substituents in a defined orientation. Behavioural characterization using the mouse head-twitch response, a 5-HT2A receptor-mediated proxy for hallucinogenic activity, found LSZ to be essentially equipotent with LSD and to produce a comparable inverted-U dose-response curve. It appeared on the research-chemical market around 2013, typically distributed on blotter paper, and undergoes hepatic N-dealkylation and hydroxylation similar to other lysergamides. Its constrained geometry makes it a useful probe for the conformational requirements of ligand binding at the 5-HT2A receptor.

effects

Serotonin

targets

5-HT2A receptor, 5-HT2C receptor, 5-HT1A receptor

suppliers

reference only